HealthTree

Showing 149 trials matching your filters.

Cord Blood Transplant in Adults With Blood Cancers

Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the ...

DRUG: Conditioning Chemotherapy

BIOLOGICAL: Cord blood graft

Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphobla...

This phase I/II studies the side effects of pembrolizumab and blinatumomab and to see how well they work in treating participants with acute lymphoblastic leukemia that has come back or has not responded to the treatment. Monoclonal antibodies, such ...

BIOLOGICAL: Blinatumomab

OTHER: Laboratory Biomarker Analysis

BIOLOGICAL: Pembrolizumab

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Und...

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therap...

DRUG: Fludarabine

RADIATION: Total-Body Irradiation

PROCEDURE: Donor Lymphocyte Infusion

DRUG: Cyclophosphamide

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Melphalan

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Diagnostic Imaging

PROCEDURE: Biospecimen Collection

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

This is a phase I/II clinical trial assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase. The tolerability of CM4620 when given to patients receiving frontline chemotherapy will...

DRUG: CM4620

Inotuzumab Ozogamicin in Treating Patients with B-cell Acute Lymphocytic Leukemia with Positive Mini...

This phase II trial studies how well inotuzumab ozogamicin works in treating patients with B-cell acute lymphocytic leukemia with positive minimal residual disease. Inotuzumab ozogamicin is a monoclonal antibody called inotuzumab linked to a toxic ag...

BIOLOGICAL: Inotuzumab Ozogamicin

Allo HSCT Using RIC and PTCy for Hematological Diseases

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem ce...

BIOLOGICAL: Peripheral Blood Stem Cell Transplant

DRUG: Allopurinol 300 MG

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: Bone Marrow Cell Transplant

RADIATION: Total Body Irradiation

DRUG: Sirolimus Pill

DRUG: Mycophenolate Mofetil

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic ...

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety a...

BIOLOGICAL: UCART22

BIOLOGICAL: CLLS52

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refra...

This phase I trial studies the side effects and best dose of palbociclib when given alone and in combination with sorafenib, decitabine, or dexamethasone in treating patients with leukemia that has come back (recurrent) or that does not respond to pr...

DRUG: Decitabine

DRUG: Dexamethasone

DRUG: Palbociclib

DRUG: Sorafenib

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).

GENETIC: KUR-502

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults...

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from...

RADIATION: Total-Body Irradiation

DRUG: Thiotepa

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: Busulfan

PROCEDURE: Allogeneic Bone Marrow Transplantation

DRUG: Tacrolimus

DRUG: Methotrexate

PROCEDURE: Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relaps...

The body has different ways of fighting infection and disease. No single way is effective at fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body f...

BIOLOGICAL: iC9-CAR19 cells

DRUG: Rimiducid

DRUG: Cyclophosphamide

DRUG: Fludarabine

Venetoclax Plus Inotuzumab for B-ALL

This research study is evaluating the safety and efficacy of administering venetoclax and inotuzumab ozogamicin in combination in patients with acute lymphoblastic leukemia (ALL) The names of the study drugs involved in this study are: * Venetoclax...

DRUG: Venetoclax

DRUG: Dexamethasone

DRUG: Inotuzumab Ozogamicin

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mix...

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phe...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Scan

DRUG: Calaspargase Pegol

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Leucovorin Calcium

PROCEDURE: Magnetic Resonance Imaging

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Pegaspargase

PROCEDURE: Positron Emission Tomography

DRUG: Prednisolone

OTHER: Questionnaire Administration

RADIATION: Radiation Therapy

DRUG: Thioguanine

DRUG: Vincristine Sulfate

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With R...

This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.

DRUG: SAR443579

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-A...

This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy

DRUG: Tecartus

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies o...

This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combi...

DRUG: voruciclib monotherapy

DRUG: voruciclib and venetoclax

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

The purpose of this study is to determine if it is possible to treat relapsed or refractory lymphoid malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) with a new type of T cell-based immunotherapy (therap...

BIOLOGICAL: Fully human anti CD19 CAR-T Cell Dose

DRUG: Fludarabine

DRUG: Cyclophosphamide

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Le...

This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the ...

BIOLOGICAL: Blinatumomab

DRUG: Ibrutinib

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refrac...

This phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not resp...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

DRUG: Calaspargase Pegol

DRUG: Cytarabine

PROCEDURE: Echocardiography

DRUG: Fludarabine Phosphate

DRUG: Hydrocortisone Sodium Succinate

PROCEDURE: Lumbar Puncture

DRUG: Methotrexate

PROCEDURE: Multigated Acquisition Scan

DRUG: Prednisolone

DRUG: Prednisone

DRUG: Revumenib

DRUG: Vincristine Sulfate

SPARK-ALL: Calaspargase Pegol in Adults With ALL

The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic Leukemia.

DRUG: Calaspargase pegol (S95015)

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refr...

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). I...

DRUG: Asparaginase Erwinia chrysanthemi

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Calaspargase Pegol

DRUG: Cyclophosphamide

DRUG: Cytarabine

PROCEDURE: Diagnostic Imaging

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Leucovorin Calcium

PROCEDURE: Lumbar Puncture

DRUG: Methotrexate

DRUG: Pegaspargase

DRUG: Vincristine

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescent...

This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cel...

DIAGNOSTIC_TEST: NGS-MRD

DRUG: Myeloablative allogeneic HCT with a non-TBI conditioning regimen

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy t...

BIOLOGICAL: 19-28z/IL-18 CAR T cells

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

DRUG: AVM0703

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cell...

Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease. This study combines two different ways of fighting disease with anti...

GENETIC: CD7.CAR/28zeta CAR T cells

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer...

DRUG: Dexamethasone

DRUG: Mitoxantrone

DRUG: PEG asparaginase

DRUG: Bortezomib

DRUG: Vorinostat

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Blinatumomab

DRUG: Ziftomenib

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Ref...

Background: B-cell leukemias and lymphomas are cancers that are often difficult to treat. The primary objective of this study is to determine the ability to take a patient's own cells (T lymphocytes) and grow them in the laboratory with the CD19/CD2...

BIOLOGICAL: CD19/CD22 CAR T-Cells

DRUG: Fludarabine

DRUG: Cyclophosphamide

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lympho...

This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with a pediatric-inspired chemotherapy regimen known as C10403 in treating patients with newly diagnosed B cell acute lymphoblastic leukemia. Venetoclax may...

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Daunorubicin Hydrochloride

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Pegaspargase

DRUG: Prednisone

DRUG: Venetoclax

DRUG: Vincristine Sulfate

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclopho...

This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell trans...

DRUG: Busulfan

DRUG: Fludarabine

RADIATION: Total-body irradiation

DRUG: Cyclophosphamide

DRUG: Melphalan

PROCEDURE: PBSC Hematopoietic Stem Cell Transplantation (HSCT)

PROCEDURE: Bone Marrow Hematopoietic Stem Cell Transplantation

DRUG: Post-transplant Cyclophosphamide

DRUG: Mesna

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Patient-Reported Outcomes

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults Wi...

This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), ...

BIOLOGICAL: NKX019

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refr...

This phase I trial tests the safety, side effects and best infusion dose of genetically engineered cells called anti-CD19/CD20/CD22 chimeric antigen receptor (CAR) T-cells following a short course of chemotherapy with cyclophosphamide and fludarabine...

BIOLOGICAL: Anti-CD19/CD20/CD22 CAR T-Cells

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell T...

This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the gro...

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Cyclophosphamide

BIOLOGICAL: Cytokine-treated Veto Cells

DRUG: Fludarabine

PROCEDURE: Peripheral Blood Stem Cell Transplantation

RADIATION: Total-Body Irradiation

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML,...

This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX...

DRUG: MRX-2843

Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromo...

To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.

DRUG: Blinatumomab

DRUG: Asciminib

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblas...

This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

DRUG: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates ...

DEVICE: Alpha/Beta T-cell and B-cell depleted HCT

DRUG: Blinatumomab

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Ac...

The researchers are doing this study to see if early reinfusion of tisagenlecleucel can keep participants in B-CEll ApLasia at 6 months after their first infusion. The researchers will also look at the safety of early reinfusion and how effective it ...

BIOLOGICAL: Tisagenlecleucel

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refracto...

This phase Ib trial tests the safety, side effects, and effectiveness of humanized (hu)CD19-chimeric antigen receptor (CAR) T cell therapy in treating patients with CD19 positive B-cell acute lymphoblastic leukemia (ALL) that has come back after a pe...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

BIOLOGICAL: Cetuximab

PROCEDURE: Computed Tomography

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Leukapheresis

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Positron Emission Tomography

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatmen...

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cyclophosphamide

DRUG: Cyclosporine

BIOLOGICAL: Filgrastim

DRUG: Fludarabine

DRUG: Mycophenolate Mofetil

DRUG: Mycophenolate Sodium

RADIATION: Total-Body Irradiation

DRUG: Treosulfan

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.

DRUG: Daratumumab / Hyaluronidase Injection

Gene Therapy for B-Cell Acute Lymphoblastic Leukemia

This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia (ALL).

GENETIC: Dose Level 1, VNX-101

GENETIC: Dose Level 2, VNX-101

GENETIC: Dose Level 3, VNX-101

GENETIC: Dose Level 4, VNX-101

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantat...

This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. Total body irradiation can lower the rel...

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Fludarabine Phosphate

BIOLOGICAL: Granulocyte Colony-Stimulating Factor

PROCEDURE: Hematopoietic Cell Transplantation

PROCEDURE: Intensity-Modulated Radiation Therapy

DRUG: Mycophenolate Mofetil

DRUG: Tacrolimus

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malign...

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell l...

BIOLOGICAL: Zilovertamab vedotin

Personalized NK Cell Therapy in CBT

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This ...

BIOLOGICAL: Allogeneic Natural Killer Cell Line NK-92

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Busulfan

DRUG: Clofarabine

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

BIOLOGICAL: Rituximab

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating P...

This phase II trial studies how well blinatumomab, inotuzumab ozogamicin, and combination chemotherapy work as frontline therapy in treating patients with B acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab,...

BIOLOGICAL: Blinatumomab

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

BIOLOGICAL: Inotuzumab Ozogamicin

OTHER: Laboratory Biomarker Analysis

DRUG: Mercaptopurine

DRUG: Methotrexate

BIOLOGICAL: Ofatumumab

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate

Blinatumomab Bridging Therapy

The investigator is testing the ability of a biologically active therapy in blinatumomab, an anti-CD19/CD3 bispecific T-cell engager, to further reduce residual leukemia immediately prior to HCT to improve post-HCT outcomes.

DRUG: Blinatumomab

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphobla...

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase ...

BIOLOGICAL: BEAM-201

Venetoclax Basket Trial for High Risk Hematologic Malignancies

This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic sy...

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Cytarabine

DRUG: Methotrexate

DRUG: Hydrocortisone

DRUG: Leucovorin

DRUG: Dexamethasone

DRUG: Vincristine

DRUG: Doxorubicin

DRUG: Dexrazoxane

DRUG: Calaspargase Pegol

DRUG: Erwinia asparaginase

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematol...

The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblasti...

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: PRGN-3007

This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical \[haplo\]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

DRUG: Busulfan

DRUG: Cyclophosphamide

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Haploidentical Hematopoietic Cell Transplantation

BIOLOGICAL: Lapine T-Lymphocyte Immune Globulin

PROCEDURE: Lumbar Puncture

PROCEDURE: Matched Unrelated Donor Hematopoietic Cell Transplantation

DRUG: Melphalan

DRUG: Methotrexate

PROCEDURE: Multigated Acquisition Scan

DRUG: Mycophenolate Mofetil

PROCEDURE: Myeloablative Conditioning

OTHER: Quality-of-Life Assessment

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

PROCEDURE: T-Cell Depletion Therapy

DRUG: Tacrolimus

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

This phase I/II trial studies the side effects and best dose of ADCT-602 in treating patients with B-cell lymphoblastic leukemia that has come back or does not respond to treatment. Monoclonal antibodies, such as ADCT-602, may interfere with the abil...

BIOLOGICAL: ADCT-602

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recu...

Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better tr...

BIOLOGICAL: CD19/CD22-CAR-transduced T cells

DRUG: cyclophosphamide

DRUG: fludarabine

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Tra...

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it a...

DRUG: Busulfan

DRUG: Fludarabine

PROCEDURE: PBSC Hematopoietic Stem Cell Transplantation (HSCT)

DRUG: Post-Transplant Cyclophosphamide

DRUG: Mesna

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Patient Reported Outcomes

DRUG: Melphalan

RADIATION: Total-body irradiation

DRUG: Cyclophosphamide

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient...

This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosp...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

DRUG: Cyclophosphamide

DRUG: Cyclosporine

PROCEDURE: Diagnostic Imaging

PROCEDURE: Echocardiography

DRUG: Fludarabine Phosphate

PROCEDURE: Multigated Acquisition Scan

DRUG: Mycophenolate Mofetil

OTHER: Survey Administration

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignan...

This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant pe...

PROCEDURE: TCRαβ+/CD19+ depleted Haploidentical HSCT

DRUG: Zoledronate

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

BIOLOGICAL: BAFFR-CAR T cells

A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutati...

A Phase 1/2 dose escalation / dose expansion study of DSP 5336 in patients with relapsed or refractory AML.

DRUG: DSP-5336

CD22 Redirected Autologous T Cells for ALL

This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in pediatric and young adult...

BIOLOGICAL: Cohort 1

BIOLOGICAL: Cohorts 2

BIOLOGICAL: Cohort 3

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malign...

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

BIOLOGICAL: OrcaGraft (Orca-Q)

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukem...

This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).

DRUG: Ruxolitinib

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Mercaptopurine

DRUG: Vincristine

DRUG: Pegaspargase

DRUG: Rituximab

DRUG: Methotrexate (Intrathecal Administration)

DRUG: Methotrexate (Intravenous Administration)

DRUG: Dexamethasone

DRUG: Doxorubicin

DRUG: Thioguanine

DRUG: Methotrexate Oral Product

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed o...

This phase Ib trial studies the effects of venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) that is newly diagnosed or that ...

DRUG: Dasatinib

DRUG: Methotrexate

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Venetoclax

BIOLOGICAL: Blinatumomab

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Lumbar Puncture

PROCEDURE: Biospecimen Collection

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality. This is a phase I/II study...

DEVICE: CliniMACS

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute...

The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that i...

DRUG: LP-118

DRUG: Ponatinib

DRUG: Vincristine

DRUG: Dexamethasone

DRUG: Methotrexate

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refr...

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back, or does not respond to treatment. Immunotherapy wi...

BIOLOGICAL: Blinatumomab

BIOLOGICAL: Inotuzumab Ozogamicin

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignanc...

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine ...

DRUG: Tagraxofusp

DRUG: Fludarabine

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Vincristine

DRUG: Azacitidine

DRUG: Methotrexate

DRUG: Cytarabine IT

DRUG: Hydrocortisone

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T...

A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and yo...

DRUG: Daratumumab

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed ...

This phase II clinical trial tests a chemotherapy regimen (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with or without rituximab \[DA-EPOCH+/-R\]) with the addition of targeted therapy (tafasitamab) for the trea...

DRUG: Cyclophosphamide

DRUG: Doxorubicin

DRUG: Etoposide

DRUG: Prednisone

BIOLOGICAL: Rituximab

BIOLOGICAL: Tafasitamab

DRUG: Vincristine

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Computed Tomography

PROCEDURE: Lumbar Puncture

PROCEDURE: Biospecimen Collection

Co-administration of CART22-65s and huCART19 for B-ALL

This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).

BIOLOGICAL: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)

BIOLOGICAL: Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leu...

Background: - Some people with cancer have solid tumors. Others have refractory leukemia. This may not go away after treatment. Researchers want to see if a drug called TURALIO(R) can shrink tumors or stop them from growing. Objectives: - To find ...

DRUG: TURALIO(R)

Auto Stem Cell Transplant for Lymphoma Patients

This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

DRUG: Etoposide

DRUG: BCNU

DRUG: AraC

DRUG: Melphalan

PROCEDURE: Peripheral blood stem cell transplantation

BIOLOGICAL: G-CSF

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and...

This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL and r/r B-cell NHL.

BIOLOGICAL: Azer-cel

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: IL-2

DRUG: Bendamustine

Orphan Indications for CD19 Redirected Autologous T Cells

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients w...

BIOLOGICAL: Murine CART19

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

DRUG: VIP943 (QW)

DRUG: VIP943 (BIW)

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

This trial is a limited multi-center, Phase II study to evaluate inotuzumab ozogamicin (Besponsa) in pediatric patients with MRD positive CD22-positive B-lymphoblastic leukemia (B-ALL). Some patients with newly diagnosed ALL maintain low levels of M...

DRUG: Inotuzumab ozogamicin

DRUG: Methotrexate

DRUG: Hydrocortisone

DRUG: Cytarabine

DRUG: Diphenhydramine

DRUG: Acetaminophen

DRUG: Methylprednisolone

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malig...

BIOLOGICAL: Orca-Q

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant ...

This phase I studies the side effects and best dose of total marrow and lymphoid irradiation when given together with fludarabine and melphalan before donor stem cell transplant in treating participants with high-risk acute leukemia or myelodysplasti...

DRUG: Fludarabine

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

RADIATION: Total Marrow Irradiation

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients Wit...

This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocyti...

DEVICE: Miltenyi CliniMACS Prodigy ® system

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressin...

Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease. No one way seems perfect for fighting cancers. This research combine...

GENETIC: Autologous CD5.CAR/28zeta CAR T cells

GENETIC: Allogeneic CD5.CAR/28zeta CAR T cells

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune ...

This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy f...

DRUG: Siltuximab

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 M...

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to det...

DRUG: revumenib

DRUG: cobicistat

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies

DRUG: Fludarabine

DRUG: Busulfan

DRUG: Melphalan

DRUG: Rituximab

DRUG: Levetiracetam

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Che...

The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of partici...

DRUG: Blinatumomab

DRUG: Low-intensity chemotherapy regimen

DRUG: SOC chemotherapy regimen

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a ...

PROCEDURE: Haploidentical Bone Marrow/Kidney

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

DRUG: Dasatinib

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic ...

This phase I/II trial studies the side effects and best dose of ONC201 and to see how well it works in treating patients with acute leukemia or high-risk myelodysplastic syndrome that has returned after a period of improvement (relapsed) or does not ...

DRUG: Akt/ERK Inhibitor ONC201

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation fo...

This phase I trial is to find out the best dose, possible benefits and/or side effects of 90Y-DOTA-anti-CD25 basiliximab given together with fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI) in treating patients with high-risk ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

BIOLOGICAL: Basiliximab

DRUG: Fludarabine Phosphate

DRUG: Indium In 111-DOTA-Basiliximab

DRUG: Melphalan

BIOLOGICAL: Palifermin

RADIATION: Total Lymphoid Irradiation

RADIATION: Total Marrow Irradiation

BIOLOGICAL: Yttrium Y 90 Basiliximab

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Pl...

The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymp...

DRUG: Relatlimab

DRUG: Nivolumab

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Settin...

This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survi...

DRUG: Azacitidine

DRUG: Venetoclax

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Oz...

This research study will add an anti-cancer drug (called inotuzumab ozogamicin also known as "InO") to treatment for participants with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Doctors leading this stu...

DRUG: Inotuzumab ozogamicin

DRUG: Dasatinib

DRUG: Dexamethasone

DRUG: Methotrexate

DRUG: Vincristine

DRUG: Ponatinib

DRUG: Methotrexate for Injection

PROCEDURE: Allogenic Stem Cell Transplantation

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MP...

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 sub...

DRUG: LP-118

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.

BIOLOGICAL: CD19x22 CAR T

A Phase 1, Study of BMF-500 in Adults With Acute Leukemia

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.

DRUG: BMF-500

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL ...

DRUG: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Conso...

To learn about the safety of giving the drug brexucabtagene autoleucel to participants with relapsed/refractory B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD. Also, to learn if giving bre...

DRUG: Blinatumomab

DRUG: Inotuzumab Ozogamicin

DRUG: Hyper-CVAD

DRUG: Mini-hyper-CVD

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refrac...

This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: * Venetoclax * Standard Chemotherapy (which includes cyclophos...

DRUG: Venetoclax

DRUG: Standard Chemotherapy

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative T-cells) for the treatment o...

BIOLOGICAL: CD19-CAR(Mem) T-cells

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Mesna

DEVICE: CliniMACS

PROCEDURE: Leukapheresis

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromos...

This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute lymphoblastic leukemia that has come back or does not respo...

BIOLOGICAL: Blinatumomab

DRUG: Cytarabine

DRUG: Methotrexate

DRUG: Ponatinib

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells with Chimeric...

The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease. The study will evaluate fea...

BIOLOGICAL: autologous hematopoietic stem cells added to planned CAR T

First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hemato...

This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

DRUG: 1A46 Injection

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 pri...

DRUG: AZD0486

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myel...

DRUG: ABL001

DRUG: Dasatinib

DRUG: Prednisone

DRUG: Blinatumomab

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab ...

To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuz...

DRUG: Cyclophosphamide

DRUG: Vincristine

DRUG: Blinatumomab

DRUG: Methotrexate

DRUG: Cytarabine

DRUG: Mercaptopurine

DRUG: Prednisone

DRUG: Pegfilgrastim

DRUG: Inotuzumab ozogamicin

DRUG: Rituximab

DRUG: Dexamethasone

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (h...

This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acute Lymphoblastic Leukemia (B-ALL).

BIOLOGICAL: Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Dis...

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative ...

DRUG: Fludarabine

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

DRUG: Cyclosporine A

DRUG: Mycophenylate mofetil

BIOLOGICAL: Umbilical cord blood

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell...

This is a Phase Ib study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) an...

BIOLOGICAL: AUTO1

Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patie...

This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.

DRUG: 131-I Apamistamab

BIOLOGICAL: CAR T-cell

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NP...

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

DRUG: BMF-219

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute M...

This phase I trial tests the side effects and best dose of total marrow lymphoid irradiation along with chemotherapy, with fludarabine and melphalan, with or without thiotepa, in combination with Orca-T cells for patients with acute myeloid leukemia ...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Dual-Energy Computed Tomography

PROCEDURE: Echocardiography

DRUG: Fludarabine

PROCEDURE: Magnetic Resonance Imaging

DRUG: Melphalan

PROCEDURE: Multigated Acquisition Scan

BIOLOGICAL: Partially Engineered T-regulatory Cell Donor Graft TRGFT-201

DRUG: Tacrolimus

DRUG: Thiotepa

RADIATION: Total Marrow and Lymphoid Irradiation

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase I...

DRUG: Inotuzumab Ozogamicin

Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Ce...

This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in diff...

DRUG: AKR1C3-activated Prodrug OBI-3424

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and...

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic an...

DRUG: EAGD T-cell infusion (Phase I)

DRUG: EAGD T-cell infusion (Expansion)

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted...

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is...

DEVICE: CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Ac...

This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood ...

RADIATION: Total-Body Irradiation

DRUG: Thiotepa

DRUG: Fludarabine

DRUG: Tacrolimus

BIOLOGICAL: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs

DRUG: Methotrexate

DRUG: Cyclophosphamide

BIOLOGICAL: Peripheral Blood Stem Cell

DRUG: Cyclosporine

DRUG: Sirolimus

DRUG: Busulfan

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Biospecimen Collection

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone...

The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute leukemias. Patients will either receive myeloablative conditioning or reduced inten...

OTHER: Ossium HPC Marrow, Bone Marrow Transplant

OTHER: Pre-transplant conditioning - Myeloablative (MAC)

OTHER: Pre-transplant conditioning - Reduced Intensity (RIC)

OTHER: Post-transplant treatment

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in...

BIOLOGICAL: PIT565

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematolo...

SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory A...

DRUG: SLS009

DRUG: venetoclax

DRUG: azacitidine

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Ste...

The goal of this phase II clinical study is to learn about the safety of inotuzumab ozogamicin when given with fludarabine, with or without bendamustine, melphalan, and rituximab before and after a stem cell transplant. Researchers also want to learn...

PROCEDURE: Allogeneic Bone Marrow Transplantation

DRUG: Bendamustine

BIOLOGICAL: Filgrastim-sndz

DRUG: Fludarabine

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Melphalan

PROCEDURE: Peripheral Blood Stem Cell Transplantation

BIOLOGICAL: Rituximab

DRUG: Tacrolimus

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemo...

This phase II trial compares the combination of inotuzumab ozogamicin and chemotherapy to the usual chemotherapy in treating patients with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma. Inotuzumab ozogamicin is a monoclonal ant...

DRUG: Cyclophosphamide

DRUG: Vincristine

DRUG: Dexamethasone

BIOLOGICAL: Inotuzumab Ozogamicin

DRUG: Methotrexate

DRUG: Cytarabine

DRUG: Methylprednisolone

BIOLOGICAL: Rituximab

DRUG: Prednisone

DRUG: Mercaptopurine

DRUG: Doxorubicin

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leu...

BIOLOGICAL: Rapcabtagene autoleucel single agent

DRUG: Ibrutinib

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Y...

This phase I trial studies the best dose and side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy, and to see how well they work in treating children or young adults with CD19 positive B acute lympho...

BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

OTHER: Laboratory Biomarker Analysis

OTHER: Questionnaire Administration

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 (Part 1 \[Dose Escalation\] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Pha...

DRUG: Bleximenib

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusio...

DRUG: CD22CART infusion

DRUG: Tisagenlecleucel

Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute...

With this research study has following goals * To confirm the highest tolerable dose of palbociclib in combination with chemotherapy is safe and well-tolerated. * To learn more about side effects of palbociclib in combination with chemotherapy; * To...

DRUG: Palbociclib

DRUG: Dexamethasone

DRUG: Bortezomib

DRUG: Doxorubicin

Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Ri...

This phase II trial studies the safety and efficacy of total marrow and lymphoid irradiation (TMLI) in combination with two chemotherapy drugs, etoposide and cyclophosphamide, as a preparative regimen before donor stem cell transplant in treating pat...

DRUG: etoposide

DRUG: cyclophosphamide

RADIATION: total marrow irradiation

PROCEDURE: allogeneic hematopoietic stem cell transplantation

PROCEDURE: allogeneic bone marrow transplantation

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patie...

This phase I trial studies the side effects and the best dose of intensity modulated total marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in treating patients with cancers of the blood (hematologic) that have ...

DRUG: Fludarabine Phosphate

DRUG: Melphalan

RADIATION: Intensity-Modulated Radiation Therapy

RADIATION: Total Marrow Irradiation

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Peripheral Blood Stem Cell Transplantation

PROCEDURE: Allogeneic Bone Marrow Transplantation

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Laboratory Biomarker Analysis

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infect...

This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Biospecimen Collection

DRUG: Granulocyte Colony-Stimulating Factor

DRUG: Hematopoietic Cell Transplantation Conditioning Regimen

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Pheresis

DRUG: Placebo Administration

DRUG: Stem Cell Mobilization Therapy

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

The purpose of the study is to evaluate the safety and tolerability of the study drug, calaspargase pegol, when given with multi-agent chemotherapy.

DRUG: Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)

DRUG: Calaspargase Pegol

DRUG: Rituximab

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come b...

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: CD70-CAR T cell infusion (Autologous)

DRUG: Mesna

huCART19-IL18 in CD19+ Cancers

The purpose of this study is to find the maximum dose of huCART19-IL18 cells that is safe for use in humans with CD19+ cancers.

BIOLOGICAL: huCART19-IL18

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants...

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate t...

DRUG: PRT2527

DRUG: Zanubrutinib

DRUG: Venetoclax

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission. Drugs used in chemotherapy, such as azacitidine and venetoclax, work in different ways to stop the growth of c...

DRUG: Azacitidine

DRUG: Venetoclax

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leu...

This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating patients with acute lymphoblastic leukemia. Inotuzumab ozogamicin is a mo...

BIOLOGICAL: Blinatumomab

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dexamethasone

BIOLOGICAL: Inotuzumab Ozogamicin

OTHER: Laboratory Biomarker Analysis

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Prednisone

BIOLOGICAL: Rituximab

DRUG: Vincristine

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

While chimeric antigen receptor T-cell (CAR T-cell) therapy produces impressive response rates in heavily pre-treated patients, early loss of response remains a barrier. One potential mechanism of relapse is limited CAR T-cell persistence. Pre-clinic...

DRUG: Duvelisib

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patien...

This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo expanded cord blood progenitor cells (dilanubicel) works in treating patients with blood cancer. Before the transplant, patients will receive chemotherapy (fludar...

BIOLOGICAL: Dilanubicel

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

OTHER: Laboratory Biomarker Analysis

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Electrocardiography

PROCEDURE: Computed Tomography

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (B...

DRUG: Ascentage Pharma HQP1351 bioavailable inhibitor

DRUG: Blinatumomab

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relaps...

This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing ...

BIOLOGICAL: Anti-CD19 CAR-T cells

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic ...

This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies ...

DRUG: Darzalex Faspro (Daratumumab and hyaluronidase-fihj)

DEVICE: JH-DSA Semi-Quant Screen and Response Score

Combination Chemotherapy and Nelarabine in Treating Patients with T-cell Acute Lymphoblastic Leukemi...

This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vinc...

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

DRUG: Mercaptopurine

DRUG: Methotrexate

DRUG: Nelarabine

DRUG: Pegaspargase

DRUG: Prednisone

DRUG: Venetoclax

DRUG: Vincristine Sulfate

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Be...

One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorecta...

DRUG: Vactosertib

DRUG: Fludarabine Phosphate

DRUG: Cyclophosphamide

DRUG: IL-2

DRUG: Natural Killer Cells

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for childre...

DRUG: Obinutuzumab

DRUG: Liposomal ARA-C

DRUG: Ifosfamide

DRUG: Carboplatin

DRUG: Etoposide

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukem...

This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia that has come back or ...

DRUG: Bortezomib

DRUG: Clofarabine

DRUG: Cyclophosphamide

DRUG: Dexamethasone

DRUG: Etoposide

BIOLOGICAL: Ofatumumab

BIOLOGICAL: Pegfilgrastim

BIOLOGICAL: Rituximab

DRUG: Vincristine Sulfate Liposome

UCD19 CAR T Therapy in Adults with B-ALL and MRD Positivity in CR1

This open-label, single arm Phase I trial aims to determine the safety and tolerability of anti-CD19 chimeric antigen receptor-expressing (CAR) T cells (UCD19 CAR T) in adults B-ALL that are in first complete remission with minimal residual disease (...

DRUG: CD19 Directed CAR T Cell

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for New...

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ...

PROCEDURE: Biospecimen Collection

BIOLOGICAL: Blinatumomab

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Cyclophosphamide

DRUG: Cytarabine

DRUG: Dasatinib

DRUG: Dexamethasone

DRUG: Doxorubicin Hydrochloride

PROCEDURE: Echocardiography

PROCEDURE: Electrocardiography

PROCEDURE: Lumbar Puncture

DRUG: Mesna

DRUG: Methotrexate

PROCEDURE: Multigated Acquisition Scan

DRUG: Ponatinib Hydrochloride

DRUG: Prednisone

DRUG: Vincristine Sulfate

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and ...

Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia"). The lymphoma or leukemia has come back...

GENETIC: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells

GENETIC: Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First...

This phase I trial tests the safety, side effects, and best dose of autologous anti-CD19 CAR-expressing T lymphocytes (CD19-CAR T cells) in older adults with B-cell acute lymphoblastic leukemia. Chimeric antigen receptor (CAR) T-cell therapy is a typ...

DRUG: Autologous Anti-CD19 CAR-expressing T Lymphocytes

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Cyclophosphamide

DRUG: Fludarabine

PROCEDURE: Leukapheresis

OTHER: Questionnaire Administration

Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric ...

To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment gr...

DRUG: Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)

DRUG: Treg CD34+HSPC (Orca-T)

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion wi...

DEVICE: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by...

BIOLOGICAL: HSCT with TBI Regimen

BIOLOGICAL: HSCT with Non-TBI Regimen

A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

The study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (ALL), to determine the maximum tolerated dose (MTD), and recommended phase 2 dose(s) (RP2D) of SC admin...

DRUG: Blinatumomab

Need Help?

Legal Info

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

Get the latest thought leadership on your Acute Lymphocytic Leukemia delivered straight to your inbox

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info